0001654954-23-001545.txt : 20230209 0001654954-23-001545.hdr.sgml : 20230209 20230209163557 ACCESSION NUMBER: 0001654954-23-001545 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230208 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230209 DATE AS OF CHANGE: 20230209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zomedica Corp. CENTRAL INDEX KEY: 0001684144 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38298 FILM NUMBER: 23606796 BUSINESS ADDRESS: STREET 1: 100 PHOENIX DRIVE STREET 2: SUITE 125 CITY: ANN ARBOR STATE: MI ZIP: 48108 BUSINESS PHONE: (734) 369-2555 MAIL ADDRESS: STREET 1: 100 PHOENIX DRIVE STREET 2: SUITE 125 CITY: ANN ARBOR STATE: MI ZIP: 48108 FORMER COMPANY: FORMER CONFORMED NAME: Zomedica Pharmaceuticals Corp. DATE OF NAME CHANGE: 20160908 8-K 1 zom_8k.htm FORM 8-K zom_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 8, 2023

 

ZOMEDICA CORP.

(Exact name of registrant as specified in its charter)

 

Alberta, Canada

 

001-38298

 

N/A

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

100 Phoenix Drive, Suite 125, Ann Arbor, Michigan

 

48108

(Address of principal executive offices)

 

(Zip Code)

 

Registrant's telephone number, including area code: (734) 369-2555

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, without par value

ZOM

NYSE American

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On February 8, 2023, Zomedica Corp. (the "Company") issued a press release announcing preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

The information included or incorporated by reference in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission before or after the date hereof, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1

 

Press release, dated February 8, 2023, issued by Zomedica Corp.

 

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 ZOMEDICA CORP.
    
Date: February 9, 2023By:/s/ Ann Marie Cotter

 

Name:

Ann Marie Cotter 
 Title:Chief Financial Officer 

 

 
-3-

 

 

Exhibit Index

 

 

99.1

 

Press release, dated February 8, 2023, issued by Zomedica Corp.

 

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
-4-

 

 EX-99.1 2 zom_ex991.htm EX-99.1 zom_ex991.htm

EXHIBIT 99.1

 

 

 

 

 

Zomedica Reports Preliminary Results for the Fourth Quarter and Full Year 2022

 

ANN ARBOR, MI / ACCESSWIRE / February 9, 2023 / Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported its preliminary unaudited results for the fourth quarter and year ended 2022.

 

Preliminary (unaudited) Fourth Quarter and Full Year 2022 Results:

 

 

·

 Revenue for the fourth quarter of 2022 is expected to be approximately $6.0-$6.2 million, an increase of 46-51% compared to the same prior year period, primarily driven by an increase in PulseVet® sales and the inclusion of our recently acquired Assisi® products.

 

 

 

 

·

 Revenue for the year ended 2022 is expected to be approximately $18.6-$18.9 million, an increase of 354-361% compared to the same prior year period, primarily driven by a full year’s worth of PulseVet sales and the inclusion of our recently acquired Assisi products.

 

 

 

 

·

 Gross Margin is expected to be approximately 72% for the full year 2022.

 

 

 

 

·

 Cash, Cash Equivalent, and Available-for-Sale Securities are expected to be approximately $156 million as of December 31, 2022.

 

 

 

The preliminary data presented in this press release have been prepared by, and are the responsibility of, our management. The preliminary data has not been compiled or examined by our independent auditors nor have our independent auditors performed any procedures with respect to this data or expressed any opinion or any form of assurance on such data. See “Cautionary Statement Regarding Forward-Looking Statements – Safe Harbor.”

 

Larry Heaton, Zomedica’s Chief Executive Officer, commented: “Our revenue growth accelerated throughout 2022, reaching ~$6 million (unaudited) in sales in the fourth quarter. We expect to continue to grow revenue as we launch new products in 2023, including the VetGuardian wireless vital signs monitor launched in early January, the TRUVIEW™ digital microscopy platform we plan to launch in the second quarter, and several new TRUFORMA® assays planned for launch later in the year. In addition, with substantial capital on hand, we continue to evaluate strategic business development options in the animal health sector to identify new opportunities to grow further through acquisitions.”

 

Webcast Conference Call

 

The company plans to report its final and more detailed results for the fourth quarter and full year 2022 on Form 10-K after 4:00 p.m. Eastern Time (est) on Wednesday, March 15, 2023. A conference call to review the results will follow at 4:30 p.m. est that same day.

 

About Zomedica

 

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica’s mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

 

 

 

 

Follow Zomedica

 

 

·

 Email Alerts: http://investors.zomedica.com

 

·

 LinkedIn: https://www.linkedin.com/company/zomedica

 

·

 Facebook: https://m.facebook.com/zomedica

 

·

 Twitter: https://twitter.com/zomedica

 

·

 Instagram: https://www.instagram.com/zomedica_inc

 

Cautionary Statement Regarding Forward-Looking Statements – Safe Harbor

 

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

 

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

 

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the finalization of the accounting procedures necessary to report our financial results for 2022, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

 

 

 

 

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

 

Contact:

Dave Gentry

RedChip Companies Inc.

1-800-RED-CHIP (733-2447)

Or 407-491-4498

ZOM@redchip.com

 

 

 

 EX-101.SCH 3 zom-20230208.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 zom-20230208_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity Address Country Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Entity File Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Entity Incorporation State Country Code EX-101.CAL 5 zom-20230208_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 zom-20230208_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 zom-20230208_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 8 zom_ex991img1.jpg begin 644 zom_ex991img1.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 08, 2023
Cover [Abstract]  
Entity Registrant Name ZOMEDICA CORP.
Entity Central Index Key 0001684144
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Feb. 08, 2023
Entity Address Country CA
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity File Number 001-38298
Entity Address Address Line 1 100 Phoenix Drive
Entity Address Address Line 2 Suite 125
Entity Address City Or Town Ann Arbor
Entity Address State Or Province MI
Entity Address Postal Zip Code 48108
City Area Code 734
Local Phone Number 369-2555
Security 12b Title Common Shares, without par value
Trading Symbol ZOM
Security Exchange Name NYSEAMER
Entity Incorporation State Country Code A0
XML 10 zom_8k_htm.xml IDEA: XBRL DOCUMENT 0001684144 2023-02-08 2023-02-08 iso4217:USD shares iso4217:USD shares 0001684144 false A0 8-K 2023-02-08 ZOMEDICA CORP. CA 001-38298 100 Phoenix Drive Suite 125 Ann Arbor MI 48108 734 369-2555 false false false false false Common Shares, without par value ZOM NYSEAMER EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://zomedica.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-0547-EntityTaxIdentificationNumber-Missing] Submission type 8-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. zom_8k.htm [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode - zom_8k.htm 1 zom_8k.htm zom-20230208.xsd zom-20230208_cal.xml zom-20230208_def.xml zom-20230208_lab.xml zom-20230208_pre.xml zom_ex991.htm http://xbrl.sec.gov/dei/2022 true true JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "zom_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "calculationLink": { "local": [ "zom-20230208_cal.xml" ] }, "definitionLink": { "local": [ "zom-20230208_def.xml" ] }, "inline": { "local": [ "zom_8k.htm" ] }, "labelLink": { "local": [ "zom-20230208_lab.xml" ] }, "presentationLink": { "local": [ "zom-20230208_pre.xml" ] }, "schema": { "local": [ "zom-20230208.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "zom", "nsuri": "http://zomedica.com/20230208", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "zom_8k.htm", "contextRef": "From2023-02-08to2023-02-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://zomedica.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "zom_8k.htm", "contextRef": "From2023-02-08to2023-02-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0001654954-23-001545-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-23-001545-xbrl.zip M4$L#!!0 ( 'R$259!X'GDC 0 (H6 0 >F]M+3(P,C,P,C X+GAS M9,U8RV[C-A3=%^@_L-JT!2K)LC'!V' RR&,&")!) 6=:9%?0-&T3E4F5I/R8 MK^\E];8E1Y*SF*Q(WW/N6Y=DII_VFQ!MJ51,\&LG\ 8.HIR(!>.K:R=6+E:$ M,0?IK^X[NO=[ D]"!)O*-?H7E*LZ0+MF%XC(_J* ME:;2=5/TWXF="1IZ(V_P,?_]#BM@"6XY( QRR0/H0V*)B-%LJ8.A/QC[P\%P ME(->Q%+OL*0(2[)FFA(=2QRB!55LQ1$XCI* )NCV5X(>UEAN<"3I!G,3%+K= M:B_7=2^B@V2KM4:_D=^1,8,>W>?/W]!=K!BG2J$7$<;&%?4'>N3$0[=AB&:& MH=",*BJW=)&J4V0-1A!DF*O)/KQVUEI'$]_?[7;>?BY#3\@51#(8^:]/C/_K MI$A)EXW0*Q^D&9#$4D*Q#CG:(A4EWDIL_4QJJ215*",;ZG2]>!$!O!@Y X"=Q1D)$Y7 MIL,:\S/VI0BIG\)R%F9$U5NRHN,4Z4-$56U^K*0"5SJ2#;D!21E:<7HWREP. M_->O3R^V59R\5Z =ZN#!>#SVK32#GB"KC67$<_BZ /?B*L0%DM]"J!LKQQ18-;P!!)2,Y0? 6','=(Q[X M6>M\WT1L[,"&%'YT4#Y=O@BY>:!+'(?@16*ZF>\H2K"A+YA$"8QFF+.A;8GB-G"/HH87PJ[05/S ME4Q,P;Y!HI!9_#5[K%=KQ\N]@!/300SF4+),]*2*%G3).+.V!N8O0&YQ1+K( M,J;^,;2L(8;C\$]^8]=P4"D@6M_-*9$R4T@3B^"0Q&%'4N%- R?]*6H]WZTB*#+ MNT94_3#>.Z"I7YI&L*F,JBF$(Z1&_&3:G3N\DYOGDR!6SQF*V;D9SS4_N<$0 M[EO>7BU2_[IX4(36S8.,U]6#^OM(2]L9P1C]T-Y<_3VESJ8Z1\DVIC&'/:Q7 M;_?MS)=%/Q>: MGE.M\I_C[:IG!>QM.YUW< \DVJ7[*(1GM!;R\ 7V[1(12EG1\KE05G:9,C;S'M7O4H>_'_C79US_!VU2/S\.#L7OCR M*S5)?J:FGP?=2U_K0JS:G_J)OIO_ 5!+ P04 M " !\A$E6:%CFUMP! "2 P % 'IO;2TR,#(S,#(P.%]C86PN>&UL MC5,[;]LP$-X+]#]][G2:W9UJ"4S#Y0^+HLMK#5O:U0.5@:9PQ(ZX2H(I0=F'1I*7] _+SXY9-$D M2F[&]TMF/4NKGN.+Z5A9>SW0>^!!N:M M81)*M.*@P >'2T,Y+#YQ6%?,U*PQ6#,5FH+%T46CUDHW9R,.E8//_ L$&]C0 M;_??8=E:H=!:V&G9ABCV*VP4CV A)12!8:% B^:(Y8N<%.I7'FY/OC_P@U8V M/UDQ)Y5S31['7==%W232YA!G29+&CP_;':]\+BI4&#A',K""RK]XZ70ZC?OJ M /T+>7HR(5QY\;OIQ5U(WV#\2M7SB1O9=_EUI^O\'ARJ$HL!Y7@_=943K@ 3BY7"O3/ MS_#J,:S@O?+8LU^9O?;K%X)<$L[BJS6Y?0902P,$% @ ?(1)5GZ^O3.6 M @ 2P@ !0 !Z;VTM,C R,S R,#A?9&5F+GAM;+U56VO;,!1^'^P_G'D/ MVV"R;(="$YJ6M-U#(1TCW4;?BB*?Q&*R%"0YE_WZ27;L)32%9I#E(=@^W^T< MR]+%U;J4L$1CA5;#*(V3"%!QG0LU'T:5)7;]]< MO"/D\7HRAEO-JQ*5@QN#S&$.*^$*"*5[9AT:0K;HGXW/ +*X%R?GW?-K9CU+ MJYKCBVE7N?5ZH&? @W)-33*2]$F69+T.]*!G;L4, C.\$ ZYJPR3D*,58T2Y*4/MZ/'WCA:L7 ULG&FM?OX14.\"(BW)$61L(CDF:DE\9K MFT=^< #-Z(R6.,$90+CX,;GK3'_K$G/!6%#AUZLZ*Y+IDXLC(S]DGSUO[D!++:7C1 M1X7=IYXZ*9/RN'PUX=2IE':C8X.UG/^X%G'&*NG^>3&V]-W$_J%0(FQL8W^[ MEQK7#E6.>9L[R+UV(W+"!7#2_%(@?X]* C42OK$Y^G-DIOV9%/R;_:_-)37? M"R/#]JO-\QG:MGF+/)[K)MDF13E+7^ MD\=LF]A.B!X843C>Z-[Y=OD'4$L#!!0 ( 'R$25;<#0[/'@8 &PY 4 M >F]M+3(P,C,P,C X7VQA8BYX;6S-6]MNXS80?2_0?YBZ#VV!RK(5H&B, M) O'FUT8=2Z(L^VB1;&0)=HF*I$&2J\M^6.SP.,>\"%3T(_H@2=]YX0[[V[ M^/Z[LQ\TV ;(R)@PI O4 @[+-:@3-<^%X@Y3H;^,QUG!%[_I#_X M_7#]TN?2BY+$1QJ'!\M[&0_H$@(5.7$=>,[@U/$&WLD!-*=+L?,9 I\%:RQ0 M(+;,CR!$'*\(2.*0)C2"\4\!O%_[+/8W#,4^44G!^%'T#[$F=//$\&HMX.?@ M%U##P-2YN7J RRW'!'$.3E8*(F/$"] MW$M%T?D-3T]/W<2:0RO(_8)%^1@G;DY'PCD>\62X&0V2R7V!&Q@1ZIV3PQQU MR1EZSLFPO^=A3\X&0#H?C$;H'BTA(3T23QNI*([C3:0H)=?6#"WU5"+&7.7O M$K120E/#G*IAAK^I87[,+L_\!8IZH)"?[J?&K$X+L3(G]X547Q?\#C%,PRN2 MC_*5$BV'?2GYKSK\7/A,O&G*J_Z6$WB@PH_>1/W8TS+I&_2VV7[VLSW+LNNC MM\WRD>1#[$ID$A M:J1Z-V75O+F,FD3D*.BOZ*,;(BPC>YYZH>Z?7I*R?/-E0N4"8+S@@OF!R",E M29SW-':W2$CAQBQG)6_!#8EE"#>@\@:W$4YTW!*7C,;:0;.X6E)Y=0O& M#I17QZ=%B@]=".R", M9G:&9I^[0.H#F5,K+?]PAJ".VFJ:6PEG]R:@)5F^&Q1 '9!''2_C_2$%@T2# M@K?02<9A*&>!3^A6KDC,+:0,L]D[]!2+3:.(Z8 <:F@9VD2&A0QL50M_,2P$ M(K(SQ5N"T_-AKLG*@+.CAEJ2N1RTH [HH8Y761 9%HI@JX*8TP@'6,B[UK7L M2PS[NIQT(#M2,-/+=5!%=$ $1E)E!3P#(4=:+?\=0TI\2!8AV>JHHTQVNUPB MILFJ#FQ'#LUTJA6OPUKQWJ 5K\7C#OGRECW0'6GG,KUQS2HSU]S(7<==VR.T8?,0G,WYV;X"THQ4!9*Y<2MFN:T=-K$$[B MI)23N[6GGCO*A1_]C3<3&C9JIP1N03E:NEK=%)!=4XV.7(-F4A>0/J"P-)0.SV =V3I0>0V=RA-82:4EQGYMU2/6T=V:$O.^M0JQ M4V,3M;S.97L':FV@5*YW H,$U\:^=8Z"+9.2&WJ+!RPBW6>Z"K%T6FZ@=C@K M+]D[4',#I08#B8,$:+7F#\Q7OS29/\4+JLNB9+=3;2VIO-0%8P?JK.-3 M+G*&@134RH?Z:A^L)25D>)!6#[/[X=91+'_ CS$=*'X-+>,'/<>V]2#ME 24 M;2A+OI--]AS9]_6U:_T&+YN+_AJ,4J* M+ 8/5@]''K$](B>$V9:ST$H45.I!5(EJ!]%03LR**B!4L1DWP,Q"T83$H/E4 M$$R<; TU2.L'1AYG5*5TKB"EPIHBK:4I']IJR_E&\>G,D!_93\1V0[K!-9=P\:EAG\;HCR!HH1MK MS9NEF3'S1ABN5JORJE:6:AI&E4HU_/#4&[(9YA5P88$S*.VC;"MY<=5ZO1YF M1_?2,^5ZK))]'[5PGP[*-6_HK+N>9!E0 M!B%;'DHF,( )L:]_#KJ'/O^5*<23]>=(ISCNB%,@.M& MW(]Q&-[CX=7%"K_^ S27$9U(GQE5OC NLW13R M_NP>88OY;(\53D@C#TCSC-R49 M[CVT&[Q,ZS4=Y(G%B6?/ ,M>*AW._DX*: MXC[G=R579M:6Z9R*BRM 08 3Z#?>UH&+-KVL!GU07,8=$=OMZN5EX43JA/H7 MC^M#KC4/<[L5QPA'M^4"?P0N3NI3I1/B7[W-YGQC-R7\M^(&M\!X)J4+P;>U M@,Y'7"!U8OR;!\87K=T4,I:-G'&#Z]83GDF*TR2?<)[.">^=![S%IF[*MJ_ MCC!@Q9SM:6PYIUXFDR]UVC'C2WHGUG4/K*^;],F\J_4"U->2SXER*T)\5'JN MCCW\.K[G"3POTG$1]G.5&V9_Q=ZY(W^;CMU+CPNH7N*;*W<#[:,$O.KQ?T$\ M^CKBD2MQ'X7B58\>-];X]D6-Y$JX[*U?B=UH^ZL6"_WY8SU$/O"B^DHN^?8B M_S7@9Q%NU'T4CBY._:'O2VUH\@^?MV7L OY$[X;=>S&9Z_*FT.WIUE) BS$? M*]S ^J@@\YS<%*6].Y?T9U)O$R23MK-J-B"L5W M3?.5;FQ]5'F7G'G8'G0%DVHN5<8FV[7L+LA>VR=<"70; '_5GY/OL_&X#\_L M8!GSR?[G97O$/MG_@;S]#%!+ P04 " !\A$E6N=8=5U@/ I9P "@ M 'IO;5\X:RYH=&WM'6MSVKCVK^BRLYMD)L882$L(]1V6D%YFF\< O=O=+W>$ M+4!;8WLE.8']]?<2 M5:Z4"/.=P.7^Y$,I4F.C4?JWW9HJZ 4]?=GD\P^EJ5)ATS2OKJ[*\Y'PRH&8 MF-6*53.Y[W&???FU_ZFT[*Z*^Z^ZFDI07XX#,:,*9H&0#HQ*U:B^RP Q)'-R M@."Y/ DN;X73,&I6"L>)A #J%DM >C8II+05!E:KR9 'AHSI$E M*=RYY$4=JY6*97XY_31PIFQ&#>Y+17V'+4?!Q+]>CP!;TZX;/3-LK]1,;!Y1 MN8(,K?R&_ALS@597Y;F2=#XPX\9<5U[8]5WM=[?Q,*X1SH@DH8( M/+;2ES&5(]T[;A@WY@9$2EP[F4,36M..4B@#R2^8R;(I!QGX MM3:@F)TPIF)4+*-J95 5(LE/7!H32L-"OF!#KO,_P4JH\)NYW*%E)YAAIQK@ M;Y3 %#'JVBW%E<=LZ/._QM[;/X;6R3$SE4?E\8)X$%6H_6M-%2P^EVR*V#,WC7J5KW> M,G,HKL?8!BFX*(D3CTZVQD1B"_ZA!%:_.0I@[5!_3#VP;K;^9VOT,<$]\&8B M#(3V"0,%"M&)UUGDL79&OF0<38LBCTHPPBH9^TQ6\FQ*":W$A, MTIUI!J5/W,7G,6>":+2LT-UV>K_E=6%]L)V^RD,/@6>!FSZ!^Q'J&&1AKZ:5 MCENU+:?I7M,U;4F?4R1FCATIG,CG,6L^#XZ7/)@Q*B/![,2>-Z$M'9XVI<\X M?@/68$I!#!O@$E)TXYW@ ?Z+-9A@.("]V9Y:!:D*Q#VIV!B/+X^9'\RX7P1V M6VIR(,S\['-$FWGM-3.6S(0!8-_IR&.IE46+:$C^#VM:X?SHBKMJ"@:R\C-P M2*$UAG]@H'+3_K^>]X^[?>/7\^'P_+1)#L(YD8''W2,88"K4#]W_IC'5XC%F M@L_4\[-;83K\Y/QL: QZ?W:;!$WW$=$O3MJGO4]_-#<,.3EM]S_VSIJD O20 M=0=0LG_YR7I7.6J9X>-C<&!9,H%4224"?V)_/NL-N\=D,&P/NX.6F;Q]+-RK MO]R_>1Z#;N=SOS?L=0>D?79,NE\Z_VF??>R2SOGI:6\PZ)V?/>/D?J=R"AF1 M"OQ]Z);,J1^P1ILA*IDGYSW3\F:Z]W6P:]< M=!JJZ;C+;AB_;3I9G(3]G7,:-+_?/1N2?O?BO#_\SHF]B(2,*(3G*B #YF!8 M1JP:"02Q#G;=/1*,R7#*L"D27'' V)T[4^I/&&D["INMPUK].V<2AC5(:I]! MZ*K(;OK,*#A1)A5AEYCA"-W,W+WFDA_KBS(;3;L 90:+=.K2Q0) ,7_[J'QS MT5[H:*L;QV!@$=A(1%0L2&.?X,#-I?R-!)6+'4:!@+#" "OB@ %O5HXRA@SQ M9F#]%4D(81=',RHFW#?0%S=II(+TA>"3:?(FCD'>00A"'.9Y(77C@EDE&Y*D M4Y@R/="".*1T0\CQ4T7_(=8R](BQ-.H_'UTRH2 7]I*9JB!$77DYWN#!CB#. MU?ILPB56\=09M)3L/\]/N\>]3AN"@/Y%>2O?D(WO;A/ R^ OF]F[W3D%TX;L MP$4NEFP@5!(9,@9.]K M&R=D]A[N%3X%H%072%5:":B].S2J!P<;+NAI=T:>9(?Z6@$GV#I3YGPED.D2 M&H(;@\6.V>\HF),1\X(KPL>Z\03<'FD8OY$Q]U#87(+D%?-=YN)FD^2SR%/4 M9T$DO061$(7*\4*/3 8$(\ :!Z=!##)3BHT CB#47Z1MX\ #Y#@.72O')%22 M7]G= MK)IL[#FLQSQX@/%AAB/PD9Y'(W\/W]?I1X>Y688#S M_MUS!!9I:E*R$SJ UE"2)C9ANU'H"?UZD&BXRJ__8J[KKO6>](YZ9-JK5*& MCGOWW&OY+A1C %&C ZSQ)Z=@AL 6>:]0*U9$D%E"Q:9*6'5J6-6,5N1VXI5YE4>R;PMX.WY>/4!8]P%<73P M"VKZE5Q-F=[N68M,(SJ*P=I M$+OFY^/3536RB_2^/]+N/NW,]=&#$(\>X,Y3+,'JR*@6P"HZLK4$BM)&J[$M=_4NP?-?).C/MFD_*ZV9XNG/$-2P$+ 87KBF\D M>U-8--V0Z^0NOGB PM2XO 4BO^* &D6.I$"+ M8) DPCA8B]1W,."BCCZ_@9WQ0IY+A2OC9!+AAX4')7?I7KK>LHNL3):R?9VR M'':_#(W>V7'W;-@$@U\^0%B;4\C8F%A<3%S'*AV.)*P"#KW(K#MICS>*-DO3 M2?,H4"J8%;0_9"^J(-6OWB753^8&$<;U$]>SV&Q-$#:KR^LL'P[Q M\F!\OM8!<^%1*8O"K!M)3HA*A86TI:]P0/99LP5?;,6F1'09 "^(<8+JNNI@ M,1L%WJ[<>RUL>]Y#GV?)24^M;BPUXV"TKJ83#V%!^A9O&:REC_: 8Z;E/UF^F[9,_DX^+ =$6":[F"*6TBK) M'N%8C'4)A5P?\=#B MCX3/Y13GBC6W*1]Q10X/RQ:90O0(R3 BTMO@Z5E;Z(I-W,<2R/)[$J^H\+:E MV/$**?>7'X-*CH ]2"0'#>R;, "J2Y(+I=1]NQ(CK]4*8C=$VZJ8!^Y/&+8 M+2,38+Z<4L_3):01(RYCH'?DEY\:U2J8:^XQ5_^VCI:*$D8P,\GTNEU6,AI; M5ECW40WH3&O3_O)VP!4'99'1Z"\ AP42!.1Q.N)>#$G#IBI%5R:;O$O*M/H# M6>FMTSQI-_%4Z^%B65[3,/611+U)L+S$X*;?[=&,B$K\[^PP1@ MMOH^A/8->AA>=M72"<;[B)L*UTM.B^%L)LD9C=PQ=.(!Y @\#=*,O60$Z5A\ M.F0?%KH&@, 36P&YFUZ3>)R$Q@W*U^FP-C'@A?>4II=8G[QWX'@T MHL[7B0!_Z1I.X 6B^9/C,#8>%^SG'C[*"> 6)?IK2B7\*AB;'QY:^&&PDHWF MNF72FXX@/]$)Y*>CZ2(;".QK4^<6A#E)' ,F(Q_PY-EQ?=1<(,2Q_E-Z'/*> M@F7? N:=.%:@]D]Q>@'O1-3S9-_M:/(]L78"@$LNT&?VL+I '7WX^I@J2O1% MIUV,:5TW\>@ZEL"N^-5._5F^I=]__IW]UYI>KQ431AXH8:8,13;2[Z*:D%$U MWG+RQST&O_RV5>_C67OXN?\$']AZ,0E7]K,^\6;ZWQ$72>BV;?I2L OO1A!< M.S3"G7.=A2391QP\2Y@!)G7QES%&#%*2,?H[!*0/%24=,$Z.,!'1X&BDIH$ M4^=^J\CY>2Q+;G&AH0D\_&1*O-&;*.+Z-U:6^IGS(G@KW2MX<[WN*U# M[=8>U@:2VRP-?J:HN8J2#M//%"6$_KIHWG)U;-VNEFQ3F@2OY9U2P3$I5 KO M8]^%W;L#T%B!\VP"A M]A8@/'J D/FHEN[@,B>I136U_\(PN62GI4?]V>;E=Z]>3P3Q5I!X*TB\%23> M"A)O!8FW>&/[>*-N/"OSS00A_@<0]O\!4$L#!!0 ( 'R$258I&@'5SP\ M -U% - >F]M7V5X.3DQ+FAT;>U<6W?;-K;^*QAW,DW6DF3+=BZ67*_C MV'+JF3CNV#[-M"^S(!*44),$"Y"2E8?SV\^W-T")4GQ+Q\XT67FH*Y&X;.S] M[3N4W7&9I7N[8R7CO=U2EZG:^V"R?ZNKG9UN!^]VU_W#W;^TVX"5?.4O7#VL7@7Q?M_;?';][U M1*J2LB^.3M]=]$1WHRA%J3/E1*ZFPII,YFM[NT4]CT:USX]_'?BA?EK[:/_D M^.TOO=6)?7&R?_;F&%ML%%=]4:JKLBU3//QZ^/ M+\3.3J>[NQX>[JX7>^+!M^;3KNW]+1^ZHN^W*.4P5?4V0V-CL,T5,@(K>QO] MQ.1EV^D/JL?;3G5I&;O MKR93,3@FSE1A;.G$3U:E.M.YM#,\2R. MJC05ORAIQ>;&YN;G!_4C;5&S9__=.[%_]OKTK"5.CL6ZV#\X&)R?OS\^&^#+ MD1K:BOBTTZ+3;\U/CW>[I$\U;9%)C>T-TTIAY6K!\P-CB\[N>@5VT? ]\?3= M+^<#L9\IB]=Y3_QZ>O),//W;=Z\V-S?Z]33^VNV+()3P]L!DA6SEI!B MHB E+TF8QA22B_P@89*$WHQ$8334WB3M2%HE8BU'N7'0(,?"Q?)6%JK" U%8 M$U=1 (-?1YLOIG"//[M:K6A-[XL_F-E;G$HY[U[G7OK>L;1K5DU5I MZ@?L)/V3AW(ZM_B<%9M^[>1/<2)+>LX^-)&93F<]-\N&)L6&WW5?;?6#@E^[ M[[7;G:F)RBMUDY:8Q.-".Z&N"A618I5&#)60!33U"DI9JG0F_OJBL]'>T! MHE(H+.Q"+G1.@913M,SVB_;S[A.OT=:O0OLYF2DHL,;VK(T%[(6)6_0(Q\:*-UW3CO]B;O49JRS<.FW(NL3<'3]4*\A&L8,BK'U M:7.O#T$>BMY;\?=?AON*![@;Y]U7G1=M^KMS(]*WGF^WMU[\IU@7"5EF&D>N MMONR[\34D&IBAQKY?Q3+W]#YYT3G&VN<$R>\TYU0?+GY9&&U:ZS4<DU0N4[K-'S M%[49$M*1VA]"Y;,A//=6M_6E@^'Q?>O@]G7IPD,%)'C"],[O10I[JD+*C%YA@DR9&B E-' M7+OU&#+,3>E7)^^A4ZP.'5=70&+.._%*Q.5",:L%1_?&TDSKB;MQ!!P.<(;L M3E!R!B1%*JY K)AJ.!:B&ECSW@K'9I)X@SO;KS;[(M8C7B/3$;QL9 HH0"I+QB\(Q.>< M: ^$AB,[A7/%]9&]DCLFH WFLO;EEKJ< S80P[&<)H.BDQF?WA14A*ER[ZUJ MP2>$$F5KP/G8TS'][FO1VKK0\EX-(^E*<6#R1%E%YN] INE74YXD+U77\@BM M+&5?>^/*6P+GE;)69(;J>JJ4[++N47M;#ED)OT>DBMV-]C^$3&C4=F]C0Q2= MK",&W'O)Q07(%T^5*Y_1^/O+WPCUKFMB,W-0"YB-TO38P14RK5$;$;..X9(XM60 M0J+(]PV-MZ55GB%5SY6*.4*/4@10P.1B1W@ZU_G8]X?M!&D;,*I-<)3LD7,S MD1P1K-;2_2(I&7=$"LZC6&4%8DO] 7X.L\C>AS/2C,+*"--5>'8-)9EV7%;0 MK/^@:P(_L$P_GW3A$&;L+.JB2#B)GM +VG(I0IB.83,0\Y:D]$[921T)A)I_ M\$G:"FH>=,A.>'.C<_+>TGO&"?F86]LAT^FT\R$L7[P^/3L?U\@-VH/ 9C+-MO_GI#I%&'2]WN?4B)8/=^C MYY"?T70?>4?UW[/=7WZ+9N7V0;/*+ MW1R79=%;7]?Y!%$1O-Y-1O0/%)H>7AQ?F!3>ZOQ2Q3QI9)PGC61;?9/ @,KB8ZI*]_WU$4/K! MW_C_B6E@8B/M6Z,VQ$<# M%GNNB:? ;:HH]U3IK'7[8L^XO!HJH)E"^DE)?$)-MQ0T<^R[Z,ZEJ $<:"3U_0VS&;<$U3K -EV"=AD60UF_5$LOBX,) S61* MQ4E$=.4N]\5FT)3)F>?E0B&@N!_GY*@D2?VI ^7-(OY*=:T12 ME96=%^ Z"$#+,9>)IU0"X+-YRD@&*VLDJ6^%SOL1-_->\A[2034A-FX(6*H$ MYM1$S4VC7>6K?"2%I=VX,DB5#A4ZKY&Q%J^Y[8%UJ$TWJB!22$:MG*I5-]IH M V8[=5IP,N94AZK%KL9%31JI 9=6???1GV+." "G@L[49;AC^_V\!NA:*\]E:"W[<06HZ!&(5%.>D V@#K#K0"M4CLRV,2\T()>]),(8[FRS"]?IS-#2"(H4I7' M=(^PLKYE:2/J6B%:4)YWOC/>. ZT-J5"9550DYFI#>TJWX#@2JMQ)3L*:U*A MDH0OE,]O08%'8#.(.3C]^?BPW=T1*RNU%HI$3-W4@M? M4K,9>\2:KH(+4BP+7L,A)CA*,$L+3W8?X]X1YP@Q ]H:]-Y!7;/OMQ;JNQBYBK U192+ M7ANA=X'39G?-]_)Y-1^EU!N,5$YM:K[\1]$87=]H[@>J=9&2AD_'FF(0$#Y& M8D2A"LQ,JJZ"IY^8=$+F+9_5F*&V0\.\M18FTS="?H-]"" 8J=<+($1JY_S>HTL*0[-2->L>84^-%L=B,>NN3W MR(!T4C.-'T!(L?_J2AAR]8F[+&Q<+>M@GEK^(@1.)'VOA&W8[3.6[T7P! *N M/XB_=4IM4;H8P?^VF,?>Q5QWBA7#BQB(@$=]V1FO/"+A++7O[[4* M8#A;NN01;D-Q(!552 !PWN#Q;F)NJB\1"XZ-B;U9][RF4#RGWWZ$RZR(*BL$ MG0:JPO?B)OP#D=H/2'^WSE,V]QK$<>_U^G[4@O3YW08:O.!R7(=;30<6F,4J MN'2IA7=7T3A'NCQB^#0:BUX3_2TI[XKK>7U6.E4RG[TEXH!:Q8TAS!FBBV8W MO?2RS<6$:U(4O)1N/%3'R(P;_$&B8\+ MN&?^>V2LXH 2I1J,@9Y%R."3!"$?G"4J(%Q1J"<7@=YR]%BYCV!WTS'PH521;ZPV=EU< M99^'5HA'HFEPI[_/0.%U8@/V!4EVE?">&RTJ*3.,VLN MMK!NEO*2ZS9QY:U#57 >[G]C>F>$[N^G\E5/KO2LO%NIKOB;C@V']U$Y2_GZ M)MVX)ZLSU4XM[/EP=E/!$.[,I2&%N=Z(D'D@EP-D\\$K6C?5];WJK[E>,Z^H M$XJBLO=YBN&'=%_^#:!F9X^ZSYF*#Q#KA H.H>$XCQY79MWVJXV-]MG@L'WP MX_%/XNG+K:WVYO;VRV>/6WFP8GOC97M[I]O>WMYY];B0N>VW[Z M?'1-X9N/?20?^QF]'/_S*WO_#U!+ 0(4 Q0 ( 'R$259!X'GDC 0 (H6 M 0 " 0 !Z;VTM,C R,S R,#@N>'-D4$L! A0#% M @ ?(1)5FA8YM;< 0 D@, !0 ( !N@0 'IO;2TR,#(S M,#(P.%]C86PN>&UL4$L! A0#% @ ?(1)5GZ^O3.6 @ 2P@ !0 M ( !R 8 'IO;2TR,#(S,#(P.%]D968N>&UL4$L! A0#% @ M?(1)5MP-#L\>!@ ;#D !0 ( !D D 'IO;2TR,#(S,#(P M.%]L86(N>&UL4$L! A0#% @ ?(1)5A&=.*./! 8"0 !0 M ( !X \ 'IO;2TR,#(S,#(P.%]P&UL4$L! A0#% @ ?(1) M5KG6'5=8#P *6< H ( !H10 'IO;5\X:RYH=&U02P$" M% ,4 " !\A$E6*1H!U<\/ #=10 #0 @ $A) >F]M @7V5X.3DQ+FAT;5!+!08 !P ' +D! ;- ! end